HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $175.
HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $175.